Clinical Trial

IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2

Study acronym: SINAPPS2
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A randomised phase II double-blinded placebo-controlled trial designed to explore the utility of immunotherapy for patients with acute psychosis associated with anti-neuronal membranes (NMDA-receptor or Voltage Gated Potassium Channel). Primary objective: To test the efficacy of immunotherapy (IVIG and rituximab) for patients with acute psychosis associated with anti-neuronal membranes. Secondary objective: To test safety of immunotherapy (IVIG and rituximab) for patients with acute psychosis associated with anti-neuronal membranes.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2017-06-19; most recent amendment 2026-05-19.
Status change: Recruiting → Active, Not Recruiting 2026-05-19
Status change: Not Yet Recruiting → Recruiting 2018-02-15
Trial Details
NCT Number NCT03194815
Lead Sponsor University of Cambridge
Collaborators: University of Oxford
Conditions Psychosis, Autoimmune Encephalitis
Enrollment 70 participants
Start Date 2017-11-01
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-22